Recombinant Human IL-2 Protein, Animal-Free
New! Bypass reconstitution steps by using a liquid formulation of Animal-free Recombinant Human IL-2. Find out more here.
Recombinant Human IL-2 Protein, Animal-Free SummaryLearn more about Animal-Free Recombinant Proteins
The ED50 for this effect is 0.0300-0.250 ng/mL.
The specific activity of recombinant human IL-2 is >5.00 x 106 IU/mg, which is calibrated against the human IL-2 WHO International Standard (NIBSC code: 86/500).
Ala21-Thr153 (Cys145Ser), with and without an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in Sodium Acetate with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in sterile deionized water.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Animal-FreeTM Recombinant Human IL-2 (Catalog # BT-002-AFL) as measured in a cell proliferation assay using CTLL-2 mouse cytotoxic T cells. The ED50 for this effect is 0.0300-0.250 ng/mL. Two independent lotswere tested for activity and plotted on the same graph to show lot-to-lot consistency of Animal-FreeTM Recombinant Human IL-2.
2 μg/lane of Animal-Free™ Recombinant Human IL‑2 Protein (Catalog # BT-002-AFL) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 13 kDa.
Recombinant Interleukin-2 (IL-2) is expressed in E. coli and has been engineered to contain the serine for cysteine substitution found in Proleukin® (aldesleukin). Recombinant IL-2 is widely used in cell culture for the expansion of T cells. IL-2 is expressed by CD4+ and CD8+ T cells, gamma δ T cells, B cells, dendritic cells, and eosinophils (1-3). Mature human IL-2 shares 56% and 66% amino acid (aa) sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit cross-species activity (4). The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes (5-7). The 55 kDa IL-2 R alpha is specific for IL-2 and binds with low affinity. The 75 kDa IL-2 R beta, which is also a component of the IL-15 receptor, binds IL-2 with intermediate affinity. The 64 kDa common gamma chain gamma c/IL-2 R gamma, which is shared with the receptors for IL-4, -7, -9, -15, and -21, does not independently interact with IL-2. Upon ligand binding, signal transduction is performed by both IL-2 R beta and gamma c.
IL-2 is best known for its autocrine and paracrine activity on T cells. It drives resting T cells to proliferate and induces IL-2 and IL-2 R alpha synthesis (1, 2). It contributes to T cell homeostasis by promoting the Fas-induced death of naïve CD4+ T cells but not activated CD4+ memory lymphocytes (8). IL-2 plays a central role in the expansion and maintenance of regulatory T cells, although it inhibits the development of Th17 polarized cells (9-11). Thus, IL-2 may be a key cytokine in the natural suppression of autoimmunity (12, 13).
IL-2 expression and concentration can have either immunostimulatory effects at high doses or immunosuppressive effects at low doses due to its preferential binding to different receptor subunits expressed by various immune cell types. This has led to the generation of recombinant IL-2 variants aimed at modifying IL-2 receptor binding for increased antitumor efficacy (14, 15). These variants are typically used in combination with immune checkpoint inhibitors instead of as a monotherapy (14). IL-2 can be genetically engineered to express in NK cells for CAR T cell therapies, and in combination with other cytokines like IL-15, can increase cell viability and proliferation (16). In addition to adoptive cell transfer and checkpoint blockade inhibitors, cancer vaccines that boost immune responses have been combined with IL-2 treatment with promising results in recent studies (15).
In cell culture, IL-2 is a frequently used cytokine for the proliferation, differentiation, and increased antibody secretion of B cells as they transform into plasma cells in vitro (17). IL-2 is also a classically used cytokine for the expansion of NK cells, early differentiated T cells and effector memory Treg cells for adoptive cell transfer cancer immunotherapy (16, 18). GMP IL-2 is a commonly used supplement for the expansion of these cell types for cellular therapies.
- Ma, A. et al. (2006) Annu. Rev. Immunol. 24:657.
- Gaffen, S.L. and K.D. Liu (2004) Cytokine 28:109.
- Taniguchi, T. et al. (1983) Nature 302:305.
- Mosmann, T.R. et al. (1987) J. Immunol. 138:1813.
- Liparoto, S.F. et al. (2002) Biochemistry 41:2543.
- Wang, X. et al. (2005) Science 310:1159.
- Bodnar, A. et al. (2008) Immunol. Lett. 116:117.
- Jaleco, S. et al. (2003) J. Immunol. 171:61.
- Malek, T.R. (2003) J. Leukoc. Biol. 74:961.
- Laurence, A. et al. (2007) Immunity 26:371.
- Kryczek, I. et al. (2007) J. Immunol. 178:6730.
- Afzali, B. et al. (2007) Clin. Exp. Immunol. 148:32.
- Fehervari, Z.et al. (2006) Trends Immunol. 27:109.
- Xue, D. et al. (2021) Antib Ther. 4:123.
- Wolfarth, A.A. et al. (2022) Immune Netw. 22:e5.
- Koehl, U. et al. (2015) Oncoimmunology. 5:e1115178.
- Marsman, C. et al. (2022) Front. In Immunol. 13:815449.
- Chamucero-Millares, J.A. et al. (2021) Cellular Immunol. 360:104257.
Manufacturing SpecificationsAnimal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.
- All molecular biology procedures use animal-free media and dedicated labware.
- Dedicated fermentors are utilized in committed animal-free areas.
- Protein purification columns are animal-free.
- Bulk proteins are filtered using animal-free filters.
- Purified proteins are stored in animal-free containers in a dedicated cold storage room.
- Low Endotoxin Level.
- No impairment of biological activity.
- High quality product obtained under stringent conditions.
- For ex vivo research or bioproduction, additional documentation can be provided.
Product Specific NoticesProleukin® is a registered trademark of Clinigen Holdings Limited.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
GMP Recombinant Proteins
Reviews for Recombinant Human IL-2 Protein, Animal-Free
There are currently no reviews for this product. Be the first to review Recombinant Human IL-2 Protein, Animal-Free and earn rewards!
Have you used Recombinant Human IL-2 Protein, Animal-Free?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image